Detailed Narrative
Robust Financial Performance in FY25
Windlas Biotech delivered strong financial results for FY25, with revenue growing 20.4% year-on-year to INR759 crores. Q4 FY25 also saw robust performance, with revenue increasing 18.3% to INR202.7 crores. The company achieved its highest-ever EPS post listing at INR29.19 for FY25. EBITDA for FY25 grew 20% to INR94.1 crores, and for Q4 FY25, it increased 16% to INR25.5 crores, demonstrating sustained operating margins.
Key Segmental Growth Drivers
The Generic Formulations CDMO vertical recorded a 15% YoY increase in revenue for both FY25 (INR555.1 crores) and Q4 FY25 (INR147.2 crores), driven by new customer additions and an expanded product portfolio. The Trade Generics and Institutional vertical showed significant growth, with FY25 revenue surging 41% to INR172.1 crores and Q4 FY25 revenue growing 31% to INR45.5 crores. The Exports vertical also contributed positively, reporting a 19% YoY increase to INR32.6 crores in FY25 and 12% growth to INR10 crores in Q4 FY25.
Injectable Facility Ramp-up and Future Potential
The new injectable facility, which incurred INR145 million in incremental depreciation in FY25, contributed approximately INR6 crores in revenue in Q4 FY25. While currently in a ramp-up phase involving customer approvals and stability data validation, management expects injectable utilization to reach 75% at peak. The long-term strategy is to prioritize exports for injectables, as these markets offer stronger margin opportunities, and the company is actively working towards achieving breakeven for this new dosage form.
Strategic Capacity Expansion and Plant 6 Integration
Windlas Biotech has strategically expanded its manufacturing capabilities, utilizing the Plant 2 extension in Q4 FY25 to accommodate future growth. The recently acquired Plant 6 oral solids facility is undergoing modernization and retrofit, with commercialization targeted within FY26. This expansion is crucial for achieving the company's goal of delivering INR1,000 crores in oral solids revenue, in addition to INR90 crores from injectables, once fully operational.
Efficient Capital Management and Liquidity Position
The company maintained a highly efficient working capital cycle of 14 days for two consecutive years, significantly lower than industry peers. It reported robust liquidity of INR213 crores, with INR223 crores invested in liquid funds and fixed deposits (INR16 crores in FDs, >INR220 crores in mutual funds). Windlas Biotech also proposed a dividend of INR12.1 crores (INR5.8 per share) for FY25, consistent with its policy of distributing 20% of profits, and is exploring M&A opportunities for dosage form expansion.
Trade Generics Market Strategy and Aspiration
The trade generics business, a key growth driver, operates in a highly distributed market. The company currently caters to about 1,000 stockists and aims to expand its reach to 5,000-6,000 stockists across India using a geography-specific, manpower-light model tailored to local needs. Despite limited external data for this segment, Windlas Biotech aspires to reach the scale of larger players like Cipla and Alkem, which are at INR2,000+ crores, indicating ambitious long-term growth targets.